OmniUltra Platform Overview - OmniUltra is the first and only transgenic chicken producing antibodies on a human framework with ultralong CDRH3s, similar to those found in cows[24] - Ultralong CDRH3s can reach binding pockets inaccessible to other antibodies, and can be cleaved to create Picobodies, the smallest functional antibody fragment[24] - OmniUltra is engineered for *in vivo* optimization, generating molecules pre-selected for function, affinity, and structural stability, potentially uncovering novel binding domains[27] - The platform leverages a transgenic chicken host to deliver biologically-optimized structured peptides, unlike phage display or other peptide discovery technologies[28] Competitive Advantages and Biological Intelligence - Antibodies generated *in vivo* are naturally optimized for specificity and developability[37] - The immune system in engineered transgenic animals creates optimized antibodies for human therapeutics, termed Biological Intelligence, increasing the efficiency and probability of success in therapeutic antibody discovery[37] - Greater evolutionary distance yields greater immunogenicity and more antibody diversity in chicken platforms[38] Epitope Coverage and Peptide Discovery - OmniUltra chickens are immunoresponsive to a variety of antigen targets[42] - Ultralong CDRH3 IgG clones bind to overlapping and novel epitopes[45] - OmniUltra can identify naturally-optimized peptide sequences that can be chemically synthesized as picobodies and retain antibody-like affinity and specificity to the immunized target[49] Market Opportunities and Expansion - The estimated total available commercial therapeutic market in 2034 is over $1 trillion, including peptides ($332 billion), bi-specifics ($460 billion), CAR-T ($224 billion), and radiopharma ($14 billion)[64] - Expansion into peptides provides an opportunity to drive service revenue and increases the potential audience of new partners by adding >130 peptide companies[66, 68]

AI与生物智能的对比 - AI擅长高速计算和学习，处理海量数据，速度远超人类大脑 [4] - AI拥有理论上无限的记忆能力，可以无损存储知识 [4] - AI能够实现无缝即时通讯，打破语言和距离的限制 [5] - 生物智能拥有情感、意识和主观体验，这是人类独有的 [5] - 人类擅长以创造力和直觉解决模糊问题 [6] AI的局限性 - AI无法真正感受喜悦或悲伤，即使通过代码模拟同理心 [6] - AI无法像人类一样理解抽象概念，缺乏直觉和创造力 [3][7] - AI的每一次突破都源于人类的创造力，其目的是服务于人类 [7] AI与人类的合作 - AI不会取代人类，而是与人类合作，成为强大的伙伴 [2] - AI可以分析数据提出新的科学理论，人类则提供创造性的见解来解释其意义 [9] - AI可以作为助手来增强人类的潜力，推动人类进步 [10] 行业发展方向 - 行业应拥抱AI，但不能将其误认为人类的替代品 [11] - 生物智能引导数字智能，未来的发展将仅受人类想象力的限制 [11] - 行业发展的关键在于如何与AI协作，实现优势互补 [9]

TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Table of Contents As filed with the Securities and Exchange Commission on February 6, 2023 Registration No. 333-268613 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 2 OMNIAB, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 8731 98-1584818 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identif ...

Table of Contents As filed with the Securities and Exchange Commission on January 5, 2023 Registration No. 333-268613 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 OMNIAB, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 8731 98-1584818 (I.R.S. Employer Identifi ...